Dimitris Voliotis, M.D., has been appointed chief development officer, CureVac AG. Dr. Voliotis will lead the company’s R&D activities from discovery to regulatory filing and serve on the executive team. Dr. Voliotis will be based at the company’s Boston location, travelling regularly to the Germany-based sites in Tübingen and Frankfurt.

“We are excited to welcome Dimitris to CureVac. He is a highly experienced leader with a strong track record in drug development and regulatory approvals, and translating science into effective therapies for patients,” said Dan Menichella, chief executive officer of CureVac. “Led by Dimitris, our clinical development organization will now be structured to better align with our efforts to more rapidly bring forward highly transformative mRNA-based products for patients suffering or at risk for cancer, rare diseases and infectious disease.”

Dr. Voliotis has more than 10 years of experience working in academic and clinical research, and more than 15 years in the pharmaceutical industry serving in global development leadership positions spanning preclinical-clinical transition, early development to late development, regulatory submissions and product life cycle management. He has worked both in the U.S. as well as in Europe. Previously, he served as senior vice president and head, Global Clinical Development for Eisai Inc.’s global Oncology Business Group. Prior to that, he spent 12 years at Bayer Healthcare in several different senior development roles. Over the course of his career, Dr. Voliotis has been instrumental in the development and approval of multiple cancer therapies.